Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

NCT07507318 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Chidamide

Sponsor

Rong Tao